FindTrial
Sign In

Clinical response of recurrence risk and the SGLT2 inhibitor of the ischemic heart disease

Clinical response of recurrence risk and the SGLT2 inhibitor of the ischemic heart disease - Clinical response of recurrence risk and the SGLT2 inhibitor of the ischemic heart disease

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023103
Enrollment
100
Registered
2016-07-11
Start date
2016-07-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the patients of ischemic heart disease and type2 DM who performed elective percutaneous coronary intervention

Interventions

The SGLT2 inhibitor limits it to empagliflozin 10mg or 25mg. We do not give the SGLT2 inhibitor in the control group.

Sponsors

Mito Kyodo General Hospital , Tsukuba University Hospital Mito Clinical Education and Training Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The patients with ischemic heart disease and type2 DM who will be performed elective PCI.

Exclusion criteria

Exclusion criteria: (1)hemodyaliysis (2)eGFR<30ml/min/1.73m2 (3)possibility of the dehydration

Design outcomes

Primary

MeasureTime frame
death,or hospitalization due to heart failure and unstable angina—

Secondary

MeasureTime frame
chest X-ray, body weight, blood pressure, haert rate, renal function, liver function, serum lipid, UCG, optical coherence tomografy—

Countries

Japan

Contacts

Public ContactEiji Ojima

Mito Kyodo General Hospital , Tsukuba University Hospital Mito Clinical Education and Training Cente Department of cardiology

ojima-tuk@umin.ac.jp+81-29-231-2371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026